Dosing recommendations for your patients

Once-Daily Dosing Icon
Once-Daily Dosing Icon

Once-daily dosing

  • In patients with volume depletion, correcting this condition prior to initiation of FARXIGA is recommended1
  • Assess renal function prior to initiation of FARXIGA therapy and then as clinically indicated
In patients with CKD at risk of progression, to reduce the risk of sustained eGFR decline, ESKD, CV death, and hospitalization for heart failure
  • No titration
FARXIGA 10 mg Tablet
Recommended dose
10 mg
 
Contraindicated
Dialysis

Not recommended for initiation of treatment in eGFR <25 mL/min/1.73 m2.

In patients with HFrEF, to reduce the risk of CV death and hospitalization for heart failure
  • Complements existing heart failure therapy
  • No titration
FARXIGA 10 mg Tablet
Recommended dose
10 mg
 
Contraindicated
Dialysis

Not recommended for initiation of treatment in eGFR <25 mL/min/1.73 m2.

In patients with T2D and either multiple CV risk factors or eCVD, to reduce the risk of  hospitalization for heart failure
  • No titration
FARXIGA 10 mg Tablet
Recommended dose
10 mg
 
Contraindicated
Dialysis

Not recommended for initiation of treatment in eGFR <25 mL/min/1.73 m2.

In patients with T2D, for glycemic control
  • AM dosing
  • With or without food
FARXIGA 5 mg Tablet
Recommended
starting dose
5 mg
FARXIGA 10 mg Tablet
Additional
A1C control
10 mg
 
Contraindicated
Dialysis

FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m2. FARXIGA is likely to be ineffective in this setting based upon its mechanism of action.

FARXIGA tablets shown are not actual sizes.


CKD=chronic kidney disease; CV=cardiovascular; eCVD=established cardiovascular disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; HFrEF=heart failure with reduced ejection fraction; T2D=type 2 diabetes.

Learn More About FARXIGA and Your Specialty

IMPORTANT SAFETY INFORMATION FOR FARXIGA